The average one-year price target for GLENMARK PHARMACEUTICALS (NSE:GLENMARK) has been revised to 594.15 / share. This is an increase of 15.58% from the prior estimate of 514.08 dated May 10, 2023.
Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) outperformed the Pharmaceuticals industry on the basis of its ROE – producing a higher 11.78% relative to the peer average of 11.47% over the past 12 ...
The company informed exchanges that it has received the EIR from the US FDA for its formulations manufacturing facility in Monroe, North Carolina, with a Voluntary Action Indicated (VAI) status ...
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic ...
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic ...
Shares of drug maker Glenmark Pharma witnessed rise on Thursday (19 May) on both BSE and NSE after the company said that it has received the final approval from the US Food and Drug Administration for ...
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback